Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jaguar Health (JAGX) Raw Materials (2018 - 2025)

Jaguar Health (JAGX) has disclosed Raw Materials for 8 consecutive years, with $2.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Raw Materials rose 4.84% to $2.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.0 million, a 4.84% increase, with the full-year FY2024 number at $1.8 million, down 10.06% from a year prior.
  • Raw Materials was $2.0 million for Q3 2025 at Jaguar Health, up from $1.9 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $2.2 million in Q1 2024 to a low of $701000.0 in Q2 2021.
  • A 5-year average of $1.8 million and a median of $1.9 million in 2025 define the central range for Raw Materials.
  • Peak YoY movement for Raw Materials: soared 178.46% in 2022, then fell 14.58% in 2025.
  • Jaguar Health's Raw Materials stood at $1.2 million in 2021, then soared by 68.35% to $2.1 million in 2022, then fell by 2.09% to $2.1 million in 2023, then decreased by 10.06% to $1.8 million in 2024, then rose by 7.68% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for JAGX's Raw Materials are $2.0 million (Q3 2025), $1.9 million (Q2 2025), and $1.9 million (Q1 2025).